1. Sonodynamic therapy on chemically induced mammary tumor: pharmacokinetics, tissue distribution and sonodynamically induced antitumor effect of gallium-porphyrin complex ATX-70
- Author
-
Nobuo Okuyama, Nagahiko Yumita, Kazuaki Sasaki, and Shin-ichiro Umemura
- Subjects
Cancer Research ,medicine.medical_specialty ,Porphyrins ,Time Factors ,9,10-Dimethyl-1,2-benzanthracene ,Ultrasonic Therapy ,Mammary gland ,chemistry.chemical_element ,Antineoplastic Agents ,Toxicology ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Pharmacokinetics ,Internal medicine ,medicine ,Distribution (pharmacology) ,Animals ,Pharmacology (medical) ,Tissue Distribution ,Gallium ,Pharmacology ,Mammary tumor ,Photosensitizing Agents ,business.industry ,Sonodynamic therapy ,Ultrasound ,Mammary Neoplasms, Experimental ,Porphyrin ,Combined Modality Therapy ,Rats ,Endocrinology ,medicine.anatomical_structure ,Oncology ,chemistry ,Area Under Curve ,Cancer research ,Female ,Drug Screening Assays, Antitumor ,business - Abstract
Sonodynamically induced antitumor effect of a gallium porphyrin complex, ATX-70 was evaluated on a chemically induced mammary tumor in Sprague-Dawley rats. The timing of 24 h after the administration of ATX-70 was chosen for ultrasonic exposure, based on pharmacokinetic analysis of ATX-70 concentrations in the tumor, plasma, skin, and muscle. At an ATX-70 dose not less than 2.5 mg/kg and at a free-field ultrasonic intensity not less than 3 W/cm(2), the synergistic effect between ATX-70 administration and ultrasonic exposure on the tumor growth inhibition was significant. These results suggest that ATX-70 is a potential sonosensitizer for sonodynamic treatment of spontaneous mammary tumors.
- Published
- 2006